During the phase I clinical trial involving hTERT- and WT-1-specific CD8+ T cells, approximately 43% of patients exhibited hTERT-reactive CD8+ T cells (61 patients out of 142 cancer patients), and 30–35% displayed WT-1-specific CD8+ T cells (data not shown). This evidence concerns the gene WT1 and cancer.